Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Follicular 17Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 6Lymphoma 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 3Leukemia 3Neoplasms 2Bronchiolitis Obliterans Syndrome 2Tumor Lysis Syndrome 1Solid Tumors 1Recurrence 1Oncology Patients Receiving Chemotherapy 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Indolent Non-Hodgkin's Lymphoma 1Chromosome 17 deletion 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1Anemia 1

Interventions

ibrutinib 4fludarabine phosphate 4fludarabine 4Rituximab 4Bendamustine Hydrochloride 3blinatumomab 2Melphalan 2Lenalidomide 2Cyclophosphamide 2Busulfan 2Alemtuzumab 2thymoglobulin 1sargramostim 1pirtobrutinib 1pegaspargase 1palbociclib 1ofatumumab 1obinutuzumab 1lirilumab 1copanlisib 1Vincristine 1RFT5-SMPT-dgA immunotoxin 1Prednisone 1Prednisolone 1Mycophenolic Acid 1Methotrexate 1Mesna 1Leukapheresis 1Immunotherapy, Adoptive 1Hydrocortisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Lymphoid × obinutuzumab × Clear all
NCT01680991 2016-04-25

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Hoffmann-La Roche

Phase 1 Completed
48 enrolled 27 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡